A. Esfandiari

发表

Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

Yi-Hsuan Ho, J. Lunec, P. Lovat, 2017, British Journal of Cancer.

Modulation of p53 signalling and response to MDM2-p53 binding antagonists

A. Esfandiari, 2016 .

Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner

J. Lunec, S. Nakjang, Thomas A. Hawthorne, 2016, Molecular Cancer Therapeutics.

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

J. Lunec, I. Hardcastle, R. Griffin, 2016, Oncotarget.

ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma

Yi-Hsuan Ho, J. Lunec, P. Lovat, 2018, Cancers.

Bispecific antibodies in oncology

Rachel M. Webster, S. Cassidy, A. Esfandiari, 2022, Nature Reviews Drug Discovery.

Title : Chemical inhibition of wild-type p 53 induced phosphatase 1 ( WIP 1 / PPM 1 D ) by GSK 2830371 potentiates the sensitivity to MDM 2 inhibitors in a p 53-dependent manner

J. Lunec, S. Nakjang, Thomas A. Hawthorne, 2018 .

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models

B. Elenbaas, D. Hochhauser, J. Hartley, 2018, Oncotarget.

Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.

J. Lunec, M. Hogarty, D. Tweddle, 2018, International journal of oncology.

Comparison of pyrrolobenzodiazepine dimer bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, and antibody-drug conjugate efficacy and toxicity.

R. Tammali, J. Hartley, E. Rosfjord, 2022, Molecular Cancer Therapeutics.